BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Testicular cancer AND RBM10, GPATC9, 8241, ENSG00000182872, CTD-2522E6_5, GPATCH9, KIAA0122, P98175, MGC1132, DXS8237E, ZRANB5, MGC997 AND Prognosis
667 results:

  • 1. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
    Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
    Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. New insights on testicular cancer prevalence with novel diagnostic biomarkers and therapeutic approaches.
    Sadek KM; AbdEllatief HY; Mahmoud SFE; Alexiou A; Papadakis M; Al-Hajeili M; Saad HM; Batiha GE
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2052. PubMed ID: 38507271
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Review on Sertoli-Leydig Cell Tumours of the Ovary.
    Muscat C; Calleja-Agius J
    Discov Med; 2024 Feb; 36(181):234-247. PubMed ID: 38409829
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Survival differences in non-seminoma testis cancer patients according to race/ethnicity.
    Incesu RB; Barletta F; Tappero S; Piccinelli ML; Garcia CC; Morra S; Scheipner L; Tian Z; Saad F; Shariat SF; Ahyai S; Longo N; Chun FKH; de Cobelli O; Terrone C; Briganti A; Tilki D; Graefen M; Karakiewicz PI
    Cancer Epidemiol; 2024 Apr; 89():102538. PubMed ID: 38377946
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Oncological and endocrinological outcomes for children and adolescents with testicular and ovarian sex cord-stromal tumors. Results of the TGM13 National Registry.
    Fuentes C; Ouldbey Y; Orbach D; Sudour-Bonnange H; Verité C; Rome A; Dumesnil C; Thebaud E; Hameury F; Dijoud F; Chabaud S; Cote MD; Fresneau B; Faure-Conter C
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30864. PubMed ID: 38259036
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Urological cancers and ChatGPT: Assessing the Quality of Information and Possible Risks for Patients.
    Ozgor F; Caglar U; Halis A; Cakir H; Aksu UC; Ayranci A; Sarilar O
    Clin Genitourin Cancer; 2024 Apr; 22(2):454-457.e4. PubMed ID: 38246831
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Epidemiology, Management, and Survival Outcomes of Germ Cell cancer in Southern Portugal: A Population-Based Study (2008-2012).
    Brito M; Ramos M; Silva JP; Câmara G; Mayer A; Miranda A; Coelho JLP; Moreira A; Esteves S
    Clin Genitourin Cancer; 2024 Feb; 22(1):e170-e177.e1. PubMed ID: 38061978
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Pediatric Sertoli-Leydig Cell Tumors of the Ovary: An Integrated Study of Clinicopathological Features, Pan-cancer-Targeted Next-generation Sequencing and Chromosomal Microarray Analysis From a Single Institution.
    Yang B; Chour W; Salazar CG; Zamiara P; Schmidt RJ; Raca G; Shillingford N; Zhou S; Warren M; Parham DM; Pawel B; Wang LL
    Am J Surg Pathol; 2024 Feb; 48(2):194-203. PubMed ID: 37946548
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Sertoli-Leydig cell tumor: a clinicopathological analysis in a comprehensive, national cohort.
    Bekker P; Miland-Samuelsen AR; Smerdel MP; Schnack TH; Lauszus FF; Karstensen SH
    Int J Gynecol Cancer; 2023 Dec; 33(12):1921-1927. PubMed ID: 37907261
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Origin and outcome of metastatic tumours to the testes: a nationwide study.
    Woortman C; van Leenders GJLH; Hugen N; van Oijen MGH; Nagtegaal ID
    BJU Int; 2024 Mar; 133(3):305-313. PubMed ID: 37877215
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [
    Lee K; Kim YI; Oh JS; Seo SY; Yun JK; Lee GD; Choi S; Kim HR; Kim YH; Kim DK; Park SI; Ryu JS
    Sci Rep; 2023 Oct; 13(1):17619. PubMed ID: 37848723
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
    Lauritsen J; Sauvé N; Tryakin A; Jiang DM; Huddart R; Heng DYC; Terbuch A; Winquist E; Chovanec M; Hentrich M; Fankhauser CD; Shamash J; Del Muro XG; Vaughn D; Heidenreich A; Sternberg CN; Sweeney C; Necchi A; Bokemeyer C; Bandak M; Jandari A; Collette L; Gillessen S; Beyer J; Daugaard G
    Br J Cancer; 2023 Nov; 129(11):1759-1765. PubMed ID: 37777577
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors.
    Takami H; Satomi K; Fukuoka K; Nakamura T; Tanaka S; Mukasa A; Saito N; Suzuki T; Yanagisawa T; Sugiyama K; Kanamori M; Kumabe T; Tominaga T; Tamura K; Maehara T; Nonaka M; Asai A; Yokogami K; Takeshima H; Iuchi T; Kobayashi K; Yoshimoto K; Sakai K; Nakazato Y; Matsutani M; Nagane M; Nishikawa R; Ichimura K
    Sci Rep; 2023 Sep; 13(1):15760. PubMed ID: 37735187
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Excellent survival in relapsed stage I testicular cancer.
    Speicher P; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Beyer J; Akhoundova D
    BMC Cancer; 2023 Sep; 23(1):870. PubMed ID: 37715132
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Dose comparison of robustly optimized intensity modulated proton therapy (IMPT) vs IMRT and VMAT photon plans for testicular seminoma.
    Rønde HS; Kronborg C; Høyer M; Hansen J; Bak ME; Agergaard SN; Als AB; Agerbæk M; Lauritsen J; Meidahl Petersen P; Dysager L; Kallehauge JF
    Acta Oncol; 2023 Oct; 62(10):1222-1229. PubMed ID: 37683054
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Conditional survival of stage III non-seminoma testis cancer patients.
    Incesu RB; Barletta F; Tappero S; Morra S; Garcia CC; Scheipner L; Piccinelli ML; Tian Z; Saad F; Shariat SF; de Cobelli O; Ahyai S; Chun FKH; Longo N; Terrone C; Briganti A; Tilki D; Graefen M; Karakiewicz PI
    Urol Oncol; 2023 Oct; 41(10):435.e11-435.e18. PubMed ID: 37558516
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Identification of risk factors and prediction models for secondary malignant neoplasms (SMNs)-free survival and SMNs-specific survival in testicular cancer survivors.
    Fu H; Talluri S; Rai S; Liang L; Trivedi J; Ankem MK
    World J Urol; 2023 Sep; 41(9):2413-2420. PubMed ID: 37530808
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Clinicopathological analysis of nuclear protein in testis midline carcinoma].
    Zhang SH; Hu CF; Gao LN; Qiao JF; Li X; Shi SS
    Zhonghua Bing Li Xue Za Zhi; 2023 Aug; 52(8):808-813. PubMed ID: 37527985
    [No Abstract]    [Full Text] [Related]  

  • 19. [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma].
    Wang Y; Shi ZY; Shi Q; Wang S; Zhang MC; Shen R; He Y; Qiu HL; Yi HM; Dong L; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):321-327. PubMed ID: 37357002
    [No Abstract]    [Full Text] [Related]  

  • 20. Multi-cancer analysis reveals universal association of oncogenic LBH expression with DNA hypomethylation and WNT-Integrin signaling pathways.
    Young IC; Brabletz T; Lindley LE; Abreu M; Nagathihalli N; Zaika A; Briegel KJ
    Cancer Gene Ther; 2023 Sep; 30(9):1234-1248. PubMed ID: 37268816
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 34.